Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 2004 2022-12-07 15:18:38 |
2 Reference format revised. -5 word(s) 1999 2022-12-08 02:30:07 | |
3 remove blank line Meta information modification 1999 2022-12-09 09:43:41 |

Video Upload Options

Do you have a full video?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Modica, R.;  Salvia, A.L.;  Liccardi, A.;  Cannavale, G.;  Minotta, R.;  Benevento, E.;  Faggiano, A.;  Colao, A. Lipid Metabolism and Homeostasis in Neuroendocrine Neoplasms. Encyclopedia. Available online: https://encyclopedia.pub/entry/38211 (accessed on 24 June 2024).
Modica R,  Salvia AL,  Liccardi A,  Cannavale G,  Minotta R,  Benevento E, et al. Lipid Metabolism and Homeostasis in Neuroendocrine Neoplasms. Encyclopedia. Available at: https://encyclopedia.pub/entry/38211. Accessed June 24, 2024.
Modica, Roberta, Anna La Salvia, Alessia Liccardi, Giuseppe Cannavale, Roberto Minotta, Elio Benevento, Antongiulio Faggiano, Annamaria Colao. "Lipid Metabolism and Homeostasis in Neuroendocrine Neoplasms" Encyclopedia, https://encyclopedia.pub/entry/38211 (accessed June 24, 2024).
Modica, R.,  Salvia, A.L.,  Liccardi, A.,  Cannavale, G.,  Minotta, R.,  Benevento, E.,  Faggiano, A., & Colao, A. (2022, December 07). Lipid Metabolism and Homeostasis in Neuroendocrine Neoplasms. In Encyclopedia. https://encyclopedia.pub/entry/38211
Modica, Roberta, et al. "Lipid Metabolism and Homeostasis in Neuroendocrine Neoplasms." Encyclopedia. Web. 07 December, 2022.
Lipid Metabolism and Homeostasis in Neuroendocrine Neoplasms
Edit

Lipid metabolism is known to be involved in tumorigenesis and disease progression in many common cancer types, including colon, lung, breast and prostate, through modifications of lipid synthesis, storage and catabolism. Furthermore, lipid alterations may arise as a consequence of cancer treatment and may have a role in treatment resistance. Neuroendocrine neoplasms (NENs) are a heterogeneous group of malignancies with increasing incidence, whose mechanisms of cancer initiation and progression are far from being fully understood. Alterations of lipid metabolism may be common across various cancer types.

lipid metabolism cholesterol metabolic syndrome neuroendocrine neoplasm

1. Introduction

Neuroendocrine neoplasms (NENs) are a heterogeneous group of malignancies with increasing incidence, originating from cells with a neuroendocrine phenotype diffused in many different organs. The main sites of origin are the gastroenteropancreatic (GEP) tract (70%) and bronchopulmonary system (25–30%) [1][2]. NENs are mainly sporadic, but can be hereditary, associated with syndromes such as multiple endocrine neoplasia type 1 (MEN1) [3]. Diagnosis is frequently delayed because NENs are often indolent and non-functional, without specific clinical presentation or symptoms. GEP-NENs are classified according to the Ki67 index or mitotic count and differentiation in neuroendocrine tumors (NETs) with grade 1, 2 or 3 (NETs G1, G2 and G3) and neuroendocrine carcinoma (NEC). Thoracic NENs comprise typical carcinoids (TCs), atypical carcinoids (ACs), large-cell neuroendocrine carcinoma (LCNEC) and small-cell lung carcinoma (SCLC) divided according to mitotic rate and presence or absence of necrosis [4][5]. The five-year survival rate ranges from 78% to 93% in localized disease, and it decreases to 19–38% in metastatic disease [6][7]. Surgery is the best option when feasible, but a wide spectrum of systemic therapy is available for locally advanced or metastatic disease and includes somatostatin analogues (SSAs), molecular targeted therapy with everolimus and sunitinib, peptide receptor radionuclide therapy (PRRT) and chemotherapies (with different drugs such as capecitabine and temozolomide).
Lipids are a class of water-insoluble heterogeneous metabolites, with almost one million species which are involved in different cellular processes: membrane stability and processing, energy reserve, intra and extra- cellular signalling and hormone synthesis [8][9]. Lipids, in the tumor microenvironment, play not only a membrane structural function, but also a protective and communicative role. Indeed, it is known that cancer cells need a greater turnover of membrane phospholipids due to the high replication rate. The cell itself can synthesize these molecules de novo and to supply itself from the circulating pool [10][11][12]. For this reason, hypercholesterolemia has been indicated as predisposed to neoplasms. In vitro studies demonstrated that the inhibition of de novo lipid synthesis and their supply from the bloodstream is able to slow down and stop the cellular cancer replication [13][14]. This process was also reversed if the same cells were exposed to a lipid-rich environment [15]. De novo lipid synthesis by neoplastic tissues is advantageous because the integration at the level of the cell membrane takes place through an organization in clusters so as to modulate cellular signaling by favoring the interaction with tyrosine kinase receptors HER2 and IGF-1 [16][17][18][19].

2. Lipid Alterations as a Risk Factor in NENs

The identification of modifiable risk factors for NENs is important not only because of their rising incidence, but also because it may be a common risk factor for the onset of non-neuroendocrine malignancies in the same patient [20][21]

Saturated fat intake has been proposed as a possible explanation for the positive associations between meat intake and small intestinal cancer [22]. A prospective study included 60 patients who received a diagnosis of small intestinal adenocarcinomas and 80 with small bowel NETs, with the aim to evaluate the role of meat and fat intake in relation to cancer development. With an 8-year follow-up period, reported that the risk of small intestine NETs was greater in subjects in the highest compared with the lowest tertile of total fat intake (p trend = 0.03). Furthermore, the analyses of the continuous data confirmed a significant association between saturated fat intake and small bowel NETs. The production of bile acids from cholesterol, capable of inducing DNA damage-releasing reactive oxygen species, has been proposed as one of the potential underlying mechanisms [23].

Evaluation of lipid profiles was also investigated in patients with pheochromocytomas or paragangliomas (PPGLs). Indeed, hyperlipidemia in PPGLs patients may be partially related to an excess of catecholamines, and the occurrence of other malignancies has been reported [21]. The correlation between catecholamines and lipid levels was evaluated in a retrospective study enrolling 54 patients before and after surgery for PPGLs [24]. The prevalence of hyperlipidemia in these patients was 46%. On multivariate analysis, preoperative lipid levels were not significantly associated with any variable, including preoperative symptoms, body mass index, tumor location, tumor size, germline mutation or lipid-lowering medication. Preoperative serum and urinary metanephrine levels, elevated in 94.4% of patients, were associated with elevated total cholesterol and LDL levels. Interestingly, surgical resection of PPGLs was associated with an improvement in both total cholesterol, HDL and LDL levels. These findings may support a relationship between catecholamine excess and hyperlipidemia, although lipid alterations do not seem to represent a risk factor. Nevertheless, screening and monitoring of the lipid profile in PPGL patients seems appropriate [24].
The evaluation of lipid alterations as risk factors in NENs is mainly retrospective and focused on GEP-NENs in the context of metabolic syndrome. Nevertheless, the relevance of the lipid profile in NEN patients highlights the importance of evaluating the lipid profile, even when diagnosis is suspected.

3. Lipids Alteration in NETs

Despite the increase in knowledge of NENs’ molecular alterations, NEN onset and development are far from being understood [25][26]. Similarly, lipid alterations in NEN development are only partially explored. Neoangiogenesis may be modulated by lipid homeostasis in cancer. In particular, cholesterol metabolism and oxysterols, cholesterol-oxidized products, are known to be involved in tumor metabolism. Actually, oxysterols are capable of increasing tumor growth both directly by promoting tumor cell growth and indirectly by decreasing antitumor immune responses, inhibiting dendritic cell migration toward lymphoid organs [27].

Soncini et al. investigated whether the neutrophil-dependent angiogenic switch occurring during pNET formation was dependent on oxysterols. The scholars analyzed the role of oxysterols in the spontaneous development of pNETs in RIP1-Tag2 mice, demonstrating an upregulation of the Cyp46a1 enzyme. This leads to an increased synthesis of the oxysterol 24S-HC in pancreatic islets. In addition, the oxysterol 24S-HC accumulation leads to the positioning of neutrophils close to hypoxic regions that require formation of neo-vessels, with the direct induction of neoangiogenesis. The oxysterol accumulation has possible therapeutic consequences: in fact, in this experiment, the RIP1-Tag2 mice treated with the squalene synthase inhibitor showed a significant reduction in proangiogenic neutrophils and angiogenic islets, confirming the previously described link between cholesterol metabolism and neutrophil-mediated angiogenesis [28].
Moreover, comparing the RIP1-Tag2-engineered mouse model of pNETs and their cognate human cancer, a similar transcriptomic profile has been described [29]. Cyp46a1 is overexpressed in some human pNET samples, and there is a linear correlation among Cyp46a1, VEGF and tumor diameter in G1 pNET patients. This model could represent a useful tool to test combination therapies of drugs currently used in pNET patients and cholesterol-lowering compounds endowed with a well-established pharmacologic profile (e.g., statins).
On the other side, HDL cholesterol could have an indirect protective role on tumor progression, as supposed by Pereira et al. They evaluated 39 patients with well-differentiated GEP-NETs, finding that elevated IL-6 expression was associated with disease progression, and IL-6 peritumoral expression was higher in patients with low HDL cholesterol (p = 0.02). Even if a definite correlation between elevated IL-6 expression and low HDL cholesterol could not be demonstrated because of the presence of a cancer-related proinflammatory microenvironment, these data suggest that reducing inflammation could potentially increase HDL cholesterol levels and consequently could improve survival [30]. Importantly, low HDL levels could be a marker of inflammation.
Furthermore, NETs had higher abundances, compared to a non-cancer control group, of oxidized lysoglycerophospholipids, indicating that these tumors were under significant oxidative stress [31].
Oxidized lipids in cancer metabolism and their possible relationship with the immune response open the door to innovative therapeutic possibilities and a deeper understanding of the metabolic wiring of cancer cells [32][33][34].

4. Treatment-Related Lipid Alterations in NENs

Therapeutic options in NENs have considerably expanded in the last decades, and the evaluation of their safety profile should include lipid homeostasis [35]. Besides a direct effect on lipid metabolism, there could be other indirect effects due to metabolic alterations (Figure 1).
/media/item_content/202212/63913cb504f12metabolites-12-01057-g001.png
Figure 1. Treatment-related lipid alterations in NENs.
SSAs are often the first therapeutic choice in G1-G2 NETs and are widely used even in higher doses and combinations [36]. Data regarding the effect of SSAs on the lipid profile are mainly derived from studies in patients with acromegaly. In these patients, SSAs usually do not significantly modify total cholesterol and LDL cholesterol levels, whereas they may increase HDL cholesterol and decrease triglyceride concentrations [37]. In particular, 120 mg of lanreotide administered in acromegalic patients in a 48-week open-label single-arm study did not negatively affect their lipid levels [38].
Interferon alpha (IFN-a) is generally considered a second-line additive to SSA treatment in patients with refractory carcinoid syndrome or in well-differentiated NENs in clinical progression, due to its significant toxicity [39]. A retrospective study evaluated 36 patients with NENs treated with IFN-a reporting an alteration of the lipid profile in prolonged treatment, in particular, on triglyceride levels [40]. This increase in triglycerides serum levels during therapy with IFN-a has been observed in chronic viral hepatitis, in which IFN-a is more often used. A significant increase (p < 0.05) in total serum triglycerides was observed after the first month of therapy in the treated groups both in comparison to the basal level and to the control group [41].
Targeted therapies with everolimus and sunitinib may represent second-line therapeutic strategies in progressive NENs. Everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR), may determine hypercholesterolemia with multiple pathological mechanisms partly unknown. Indeed, inhibition of the mTOR may determine a lower lipid turnover by inhibiting the lipid neosynthesis and the sequestration of LDL from the circulation, [36][42].
Sunitinib, a multikinase inhibitor, has been shown to induce grade 1/2 hypothyroidism in 7% of pNEN patients. As a consequence, hypothyroidism may influence the lipid profile, but no other studies specifically addressing the lipid profile in NEN patients treated with sunitinib are currently available [43].
Finally, chemotherapy has been linked to alterations in serum lipids in cancer patients [44], but the specific alterations caused by different chemotherapy regimens remain unclear [45]. Temozolomide (one of the main chemotherapy drugs used for NENs) has been demonstrated to increase fatty acid uptake both in in vitro and in vivo models of glioblastoma. The interplay between DNA alkylation and lipid uptake is not clear, but increased fatty acid uptake in glioblastoma cells may be a strategy to react to the temozolomide-induced generation of reactive oxygen species [46]. Capecitabine has also been shown to determine hypertriglyceridemia in about 4–10% of patients, but underlying mechanisms are not fully understood. Nevertheless, acute pancreatitis and a higher incidence of cardiovascular disease may occur due to capecitabine-induced hypertrygliceridemia, as an acute and chronic complication, respectively [47]
Alteration of lipid metabolism does not seem to represent a significant safety concern in NEN therapy. Nevertheless, careful monitoring and appropriate treatment are recommended, as metabolic alterations may affect disease-free survival.

5. Lipids as Target for Anticancer Therapies

The ability of cancer cells to expand their lipidic membrane is crucial for their survival. For this reason, some studies have focused the attention on possible molecular-targeting drugs that could interfere with lipidic membrane stability. An interesting study proposed squalene epoxidase (SQLE), a key rate-limiting enzyme involved in the cholesterol biosynthetic pathway, as a potential therapeutic target in a specific subset of aggressive and difficult to treat NENs, small-cell lung cancer (SCLC). 

Moreover, the potential anticancer role of other compounds named alkyl phospholipids, has been spurred forward by recent data [48]. Alkyl phospholipids are synthetic analogues of naturally occurring membrane phospholipid esters. These agents have demonstrated significant effectiveness against skin malignancies and several types of hematological malignancies.
Lipid metabolism may represent a target, even as a supportive anticancer therapy, as proposed in combination with immune checkpoint inhibitors (ICIs), currently approved drugs even for the treatment of Merkel cell carcinoma, a rare and aggressive cutaneous NEN [49]. It has been reported that the anticancer response of CD8+ T cells could be potentiated by modulating cholesterol metabolism [50].

References

  1. Dasari, A.; Shen, C.; Halperin, D.M.; Zhao, B.; Zhou, S.; Xu, Y.; Shih, T.; Yao, J.C. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017, 3, 1335–1342.
  2. Muscogiuri, G.; Altieri, B.; Albertelli, M.; Dotto, A.; Modica, R.; Barrea, L.; Fanciulli, G.; Feola, T.; Baldelli, R.; Ruggeri, R.M.; et al. Epidemiology of pancreatic neuroendocrine neoplasms: A gender perspective. Endocrine 2020, 69, 441–450.
  3. Ruggeri, R.M.; Benevento, E.; De Cicco, F.; Fazzalari, B.; Guadagno, E.; Hasballa, I.; Tarsitano, M.G.; Isidori, A.M.; Colao, A.; Faggiano, A.; et al. Neuroendocrine neoplasms in the context of inherited tumor syndromes: A reappraisal focused on targeted therapies. J. Endocrinol. Investig. 2022, 1–22.
  4. Zatelli, M.C.; Guadagno, E.; Messina, E.; lo Calzo, F.; Faggiano, A.; Colao, A.; Albertelli, M.; Bianchi, A.; Circelli, L.; de Cicco, F.; et al. Open issues on G3 neuroendocrine neoplasms: Back to the future. Endocr. Relat. Cancer 2018, 25, R375–R384.
  5. Rindi, G.; Mete, O.; Uccella, S.; Basturk, O.; La Rosa, S.; Brosens, L.A.A.; Ezzat, S.; de Herder, W.W.; Klimstra, D.S.; Papotti, M.; et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr. Pathol. 2022, 33, 115–154.
  6. Riihimäki, M.; Hemminki, A.; Sundquist, K.; Sundquist, J.; Hemminki, K. The epidemiology of metastases in neuroendocrine tumors. Int. J. Cancer 2016, 139, 2679–2686.
  7. Yao, J.C.; Hassan, M.M.; Phan, A.T.; Dagohoy, C.G.; Leary, C.C.; Mares, J.E.; Abdalla, E.K.; Fleming, J.B.; Vauthey, J.-N.; Rashid, A.; et al. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 2008, 26, 3063–3072.
  8. De Carvalho, C.C.C.R.; Caramujo, M.J. The various roles of fatty acids. Molecules 2018, 23, 2583.
  9. Lydic, T.A.; Goo, Y.-H. Lipidomics unveils the complexity of the lipidome in metabolic diseases. Clin. Transl. Med. 2018, 7, 4.
  10. Ferro, M.; Terracciano, D.; Buonerba, C.; Lucarelli, G.; Bottero, D.; Perdonà, S.; Autorino, R.; Serino, A.; Cantiello, F.; Damiano, R.; et al. The emerging role of obesity, diet and lipid metabolism in prostate cancer. Future Oncol. 2017, 13, 285–293.
  11. Tworoger, S.S.; Huang, T. Obesity and Ovarian Cancer; Springer International Publishing: Cham, Switzerland, 2016.
  12. Hoy, A.J.; Balaban, S.; Saunders, D. Adipocyte–Tumor Cell Metabolic Crosstalk in Breast Cancer. Trends Mol. Med. 2017, 23, 381–392.
  13. Rysman, E.; Brusselmans, K.; Scheys, K.; Timmermans, L.; Derua, R.; Munck, S.; Van Veldhoven, P.P.; Waltregny, D.; Daniëls, V.W.; Machiels, J.; et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 2010, 70, 8117–8126.
  14. De Schrijver, E.; Brusselmans, K.; Heyns, W.; Verhoeven, G.; Swinnen, J.V. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res. 2003, 63, 3799–3804.
  15. Swinnen, J.V.; Roskams, T.; Joniau, S.; Van Poppel, H.; Oyen, R.; Baert, L.; Heyns, W.; Verhoeven, G. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int. J. Cancer 2002, 98, 19–22.
  16. Zhang, J.; Li, Q.; Wu, Y.; Wang, D.; Xu, L.; Zhang, Y.; Wang, S.; Wang, T.; Liu, F.; Zaky, M.Y.; et al. Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer. Cell Commun. Signal. 2019, 17, 15.
  17. Li, Y.C.; Park, M.J.; Ye, S.-K.; Kim, C.-W.; Kim, Y.-N. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am. J. Pathol. 2006, 168, 1107–1118.
  18. Pike, L.J. Growth factor receptors, lipid rafts and caveolae: An evolving story. Biochim. Biophys. Acta (BBA)—Mol. Cell Res. 2005, 1746, 260–273.
  19. Casaletto, J.B.; McClatchey, A.I. Spatial regulation of receptor tyrosine kinases in development and cancer. Nat. Rev. Cancer 2012, 12, 387–400.
  20. Massironi, S.; Campana, D.; Pusceddu, S.; Albertelli, M.; Faggiano, A.; Panzuto, F.; Smiroldo, V.; Andreasi, V.; Rossi, R.; Maggio, I.; et al. Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. Dig. Liver Dis. 2021, 53, 367–374.
  21. Canu, L.; Puglisi, S.; Berchialla, P.; De Filpo, G.; Brignardello, F.; Schiavi, F.; Ferrara, A.M.; Zovato, S.; Luconi, M.; Pia, A.; et al. A multicenter epidemiological study on second malignancy in non-syndromic pheochromocytoma/paraganglioma patients in Italy. Cancers 2021, 13, 5831.
  22. Wu, A.H.; Yu, M.C.; Mack, T.M. Smoking, alcohol use, dietary factors and risk of small intestinal adenocarcinoma. Int. J. Cancer 1997, 70, 512–517.
  23. Cross, A.J.; Leitzmann, M.F.; Subar, A.F.; Thompson, F.E.; Hollenbeck, A.R.; Schatzkin, A. A prospective study of meat and fat intake in relation to small intestinal cancer. Cancer Res. 2008, 68, 9274–9279.
  24. Good, M.L.; Malekzadeh, P.; Ruff, S.M.; Gupta, S.; Copeland, A.; Pacak, K.; Nilubol, N.; Kebebew, E.; Patel, D. Surgical Resection of Pheochromocytomas and Paragangliomas is Associated with Lower Cholesterol Levels. World J. Surg. 2020, 44, 552–560.
  25. Colao, A.; De Nigris, F.; Modica, R.; Napoli, C. Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead. Front. Endocrinol. 2020, 11, 604341, PMCID:PMC7770585.
  26. Melone, V.; Salvati, A.; Palumbo, D.; Giurato, G.; Nassa, G.; Rizzo, F.; Palo, L.; Giordano, A.; Incoronato, M.; Vitale, M.; et al. Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis. J. Transl. Med. 2022, 20, 306.
  27. Raccosta, L.; Fontana, R.; Maggioni, D.; Lanterna, C.; Villablanca, E.; Paniccia, A.; Musumeci, A.; Chiricozzi, E.; Trincavelli, M.L.; Daniele, S.; et al. The oxysterol-cxcr2 axis plays a key role in the recruitment of tumor-promoting neutrophils. J. Exp. Med. 2013, 210, 1711–1728.
  28. Soncini, M.; Corna, G.; Moresco, M.; Coltella, N.; Restuccia, U.; Maggioni, D.; Raccosta, L.; Lin, C.-Y.; Invernizzi, F.; Crocchiolo, R.; et al. 24-hydroxycholesterol participates in pancreatic neuroendocrine tumor development. Proc. Natl. Acad. Sci. USA 2016, 113, E6219–E6227.
  29. Sadanandam, A.; Wullschleger, S.; Lyssiotis, C.A.; Grötzinger, C.; Barbi, S.; Bersani, S.; Körner, J.; Wafy, I.; Mafficini, A.; Lawlor, R.T.; et al. A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics. Cancer Discov. 2015, 5, 1296–1313.
  30. Pereira, S.S.; Pereira, R.; Santos, A.P.; Costa, M.M.; Morais, T.; Sampaio, P.; Machado, B.; Afonso, L.P.; Henrique, R.; Monteiro, M.P. Higher IL-6 peri-tumoural expression is associated with gastro-intestinal neuroendocrine tumour progression. Pathology 2019, 51, 593–599.
  31. López-López, Á.; Godzien, J.; Soldevilla, B.; Gradillas, A.; López-Gonzálvez, Á.; Lens-Pardo, A.; La Salvia, A.; Riesco-Martínez, M.D.C.; García-Carbonero, R.; Barbas, C. Oxidized lipids in the metabolic profiling of neuroendocrine tumors—Analytical challenges and biological implications. J. Chromatogr. A 2020, 1625, 461233.
  32. Samudio, I.; Harmancey, R.; Fiegl, M.; Kantarjian, H.; Konopleva, M.; Korchin, B.; Kaluarachchi, K.; Bornmann, W.; Duvvuri, S.; Taegtmeyer, H.; et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J. Clin. Investig. 2010, 120, 142–156.
  33. Santos, C.R.; Schulze, A.; Claudio Santos, C.R. Lipid metabolism in cancer. FEBS J. 2012, 279, 2610–2623.
  34. Martín-Sierra, C.; Laranjeira, P.; Domingues, M.; Paiva, A. Lipoxidation and cancer immunity. Redox Biol. 2019, 23, 101103.
  35. Faggiano, A.; Calzo, F.L.; Pizza, G.; Modica, R.; Colao, A. The safety of available treatments options for neuroendocrine tumors. Expert Opin. Drug Saf. 2017, 16, 1149–1161.
  36. Lamberti, G.; Faggiano, A.; Brighi, N.; Tafuto, S.; Ibrahim, T.; Brizzi, M.P.; Pusceddu, S.; Albertelli, M.; Massironi, S.; Panzuto, F.; et al. Nonconventional Doses of Somatostatin Analogs in Patients with Progressing Well-Differentiated Neuroendocrine Tumor. J. Clin. Endocrinol. Metab. 2020, 105, 194–200.
  37. Filippatos, T.; Liberopoulos, E.; Pavlidis, N.; Elisaf, M.; Mikhailidis, D. Effects of hormonal treatment on lipids in patients with cancer. Cancer Treat. Rev. 2009, 35, 175–184.
  38. Caron, P.J.; Petersenn, S.; Houchard, A.; Sert, C.; Bevan, J.S. Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly: Data from the PRIMARYS study. Clin. Endocrinol. 2017, 86, 541–551.
  39. Niederle, B.; Pape, U.-F.; Costa, F.; Gross, D.; Kelestimur, F.; Knigge, U.; Öberg, K.; Pavel, M.; Perren, A.; Toumpanakis, C.; et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology 2016, 103, 125–138.
  40. Oberg, K.; Norheim, I.; Lind, E.; Alm, G.; Lundqvist, G.; Wide, L.; Jonsdottir, B.; Magnusson, A.; Wilander, E. Treatment of malignant carcinoid tumors with human leukocyte interferon: Long-term results. Cancer Treat. Rep. 1986, 70, 1297–1304.
  41. Ruiz-Moreno, M.; Carreño, V.; Rúa, M.; Cotonat, T.; Serrano, B.; Santos, M.; Marriott, E. Increase in triglycerides during alpha-interferon treatment of chronic viral hepatitis. J. Hepatol. 1992, 16, 384.
  42. Laplante, M.; Sabatini, D.M. An Emerging Role of mTOR in Lipid Biosynthesis. Curr. Biol. 2009, 19, R1046–R1052.
  43. Raymond, E.; Dahan, L.; Raoul, J.-L.; Bang, Y.-J.; Borbath, I.; Lombard-Bohas, C.; Valle, J.; Metrakos, P.; Smith, D.; Vinik, A.; et al. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. N. Engl. J. Med. 2011, 364, 501–513.
  44. Sharma, M.; Tuaine, J.; McLaren, B.; Waters, D.L.; Black, K.; Jones, L.M.; McCormick, S.P.A. Chemotherapy agents alter plasma lipids in breast cancer patients and show differential effects on lipid metabolism genes in liver cells. PLoS ONE 2016, 11, e0148049.
  45. He, T.; Wang, C.; Tan, Q.; Wang, Z.; Li, J.; Chen, T.; Cui, K.; Wu, Y.; Sun, J.; Zheng, D.; et al. Adjuvant chemotherapy-associated lipid changes in breast cancer patients: A real-word retrospective analysis. Medicine 2020, 99, e21498.
  46. Caragher, S.; Miska, J.; Shireman, J.; Park, C.H.; Muroski, M.; Lesniak, M.S.; Ahmed, A.U. Temozolomide treatment increases fatty acid uptake in glioblastoma stem cells. Cancers 2020, 12, 3126.
  47. Uche, A.; Vankina, R.; Gong, J.; Cho, M.; Yeh, J.J.; Kim, P.; Pan, K. Capecitabine-induced hypertriglyceridemia: A rare but clinically relevant treatment-related adverse event. J. Gastrointest. Oncol. 2018, 9, 1213–1219.
  48. Koufaki, M.; Polychroniou, V.; Calogeropoulou, T.; Tsotinis, A.; Drees, M.; Fiebig, H.H.; LeClerc, S.; Hendriks, A.H.R.; Makriyannis, A. Alkyl and alkoxyethyl antineoplastic phospholipids. J. Med. Chem. 1996, 39, 2609–2614.
  49. Gallo, M.; NIKE Group; Guarnotta, V.; De Cicco, F.; Rubino, M.; Faggiano, A.; Colao, A. Immune checkpoint blockade for Merkel cell carcinoma: Actual findings and unanswered questions. J. Cancer Res. Clin. Oncol. 2019, 145, 429–443.
  50. Yang, W.; Bai, Y.; Xiong, Y.; Zhang, J.; Chen, S.; Zheng, X.; Meng, X.; Li, L.; Wang, J.; Xu, C.; et al. Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism. Nature 2016, 531, 651–655.
More
Information
Subjects: Others
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : , , , , , , ,
View Times: 526
Revisions: 3 times (View History)
Update Date: 09 Dec 2022
1000/1000
Video Production Service